Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Research Officer | January 31, 2022 | February 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date January 31, 2022 · Filed February 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.02 · Expires 2032-01-31 | Direct | 32,319 |
Reported balance
After 2022-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 32,319 · Balance 32,319 F1: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,746 |
Reported balance
After 2022-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-31 · Grant · Acquired 4,746 · Balance 4,746 F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
F3: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2022 Filed Feb 3, 2022 01:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 4,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006588 · doc4.xml · derivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,746 Underlying: Common Stock · 4,746 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. F3 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 32,319 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001209191-22-006588 · doc4.xml · derivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,319 Underlying: Common Stock · 32,319 shares Expires 2032-01-31 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $43.24 Strike: $43.24 | $216,200.00 |
DisclosureSEC source: 0001209191-21-060281 · doc4.xml · derivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,400 Underlying: Common Stock · 5,000 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 06, 2017 and vested monthly over four years. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $104.85 | $524,260.00 |
DisclosureSEC source: 0001209191-21-060281 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,273 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $105.085. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $43.24 | $216,200.00 |
DisclosureSEC source: 0001209191-21-060281 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 22:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 3,000 | $104.75 | $314,250.30 |
DisclosureSEC source: 0001209191-21-060281 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,273 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.75 to $104.755. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 6,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · derivative · entry 6 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,376 Underlying: Common Stock · 6,376 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 38,256 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · derivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,256 Underlying: Common Stock · 38,256 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,218 | $116.70 | $142,142.31 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,273 F7 · kind: Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 803 | $116.69 | $93,705.12 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,178 F5 · kind: Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 687 | $116.67 | $80,151.81 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,456 F3 · kind: Sale of 687 shares of common stock issued upon vesting of 1,974 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,287) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:21 UTC Amendment | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 42,042 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023381 · doc4a.xml · derivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,042 Underlying: Common Stock · 42,042 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2021 Filed Feb 10, 2021 02:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 605 | $113.76 | $68,822.56 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,169 F1 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2021 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $111.81 to $116.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 23:19 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $90.73 | $204,783.70 |
DisclosureSEC source: 0001209191-20-058547 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,624 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,288 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,031) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $88.93 to $92.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,257 | $118.83 | $268,199.76 |
DisclosureSEC source: 0001209191-20-045758 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,593 F1 · kind: Sale of 2,257 shares of common stock issued upon vesting of 4,287 performance restricted stock units to cover withholding taxes, with the balance of the shares (2,030) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $118.29 to $120.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 1,049 | $43.24 Strike: $43.24 | $45,358.76 |
DisclosureSEC source: 0001209191-20-036698 · doc4.xml · derivative · entry 6 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,151 Underlying: Common Stock · 1,049 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 6, 2017 and vests monthly over four years. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 1,812 | $35.99 Strike: $35.99 | $65,213.88 |
DisclosureSEC source: 0001209191-20-036698 · doc4.xml · derivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,812 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted February 5, 2016 and vested monthly over four years. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 2,710 | $32.99 Strike: $32.99 | $89,402.90 |
DisclosureSEC source: 0001209191-20-036698 · doc4.xml · derivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,710 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,049 | $43.24 | $45,358.76 |
DisclosureSEC source: 0001209191-20-036698 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,812 | $35.99 | $65,213.88 |
DisclosureSEC source: 0001209191-20-036698 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:31 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,710 | $32.99 | $89,402.90 |
DisclosureSEC source: 0001209191-20-036698 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $35.99 Strike: $35.99 | $359,900.00 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · derivative · entry 7 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,588 Underlying: Common Stock · 10,000 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 5, 2016 and vested monthly over four years. Read SEC document |
| May 19, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 32,749 | $126.73 | $4,150,133.40 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · nonDerivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,992 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.91 to $127.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 19, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $125.98 | $1,259,800.00 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · nonDerivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,741 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| May 19, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 10,000 | $35.99 | $359,900.00 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $35.99 Strike: $35.99 | $359,900.00 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · derivative · entry 6 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,588 Underlying: Common Stock · 10,000 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 5, 2016 and vested monthly over four years. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $119.98 | $1,199,800.00 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,741 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 10,000 | $35.99 | $359,900.00 |
DisclosureSEC source: 0001209191-20-031028 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:06 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 8,682 | $105.44 | $915,454.39 |
DisclosureSEC source: 0001209191-20-028392 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,741 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $106.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:42 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,934 | $99.41 | $192,258.17 |
DisclosureSEC source: 0001209191-20-026069 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,423 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:16 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,218 | $103.31 | $125,832.55 |
DisclosureSEC source: 0001209191-20-008498 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,682 F1 · kind: Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:50 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 7,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · derivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,897 Underlying: Common Stock · 7,897 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:50 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 49,844 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · derivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,844 Underlying: Common Stock · 49,844 shares Expires 2030-02-06 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:50 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 803 | $101.44 | $81,456.16 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,587 F5 · kind: Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.67 to $103.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:50 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 605 | $103.15 | $62,405.33 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,865 F3 · kind: Sale of 605 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (545) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.98 to $104.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:50 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,013 | $103.15 | $104,489.03 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,320 F1 · kind: Sale of 1,013 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (912) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $105.04 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $35.99 Strike: $35.99 | $179,950.00 |
DisclosureSEC source: 0001209191-19-057272 · doc4.xml · derivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,830 Underlying: Common Stock · 5,000 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted February 05, 2016 and vests monthly over four years. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $115.98 | $579,900.00 |
DisclosureSEC source: 0001209191-19-057272 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,408 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 22:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $35.99 | $179,950.00 |
DisclosureSEC source: 0001209191-19-057272 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,188 | $32.99 Strike: $32.99 | $336,102.12 |
DisclosureSEC source: 0001209191-19-055228 · doc4.xml · derivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,188 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,188 | $100.34 | $1,022,297.54 |
DisclosureSEC source: 0001209191-19-055228 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,408 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.71.The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:37 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 10,188 | $32.99 | $336,102.12 |
DisclosureSEC source: 0001209191-19-055228 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 50,000 | $32.99 Strike: $32.99 | $1,649,500.00 |
DisclosureSEC source: 0001209191-19-043916 · doc4.xml · derivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,188 Underlying: Common Stock · 50,000 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $94.31 | $943,118.00 |
DisclosureSEC source: 0001209191-19-043916 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,408 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.31 to $94.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 50,000 | $92.65 | $4,632,320.00 |
DisclosureSEC source: 0001209191-19-043916 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,408 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.75 to $94.31. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:12 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 50,000 | $32.99 | $1,649,500.00 |
DisclosureSEC source: 0001209191-19-043916 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2019 Filed May 15, 2019 23:24 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,657 | $75.44 | $125,007.23 |
DisclosureSEC source: 0001209191-19-030173 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,408 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $74.33 to $76.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 9,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008638 · doc4.xml · derivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,254 Underlying: Common Stock · 9,254 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 50,005 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008638 · doc4.xml · derivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,005 Underlying: Common Stock · 50,005 shares Expires 2029-02-07 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 531 | $84.03 | $44,621.58 |
DisclosureSEC source: 0001209191-19-008638 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,065 F1 · kind: Sale of 531 shares of common stock issued upon vesting of 1,525 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (994) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.98 to $85.76. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.